Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TroFuse-031 trial: what clinicians have said so far
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- NCT07419295 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TroFuse-031 (sacituzumab tirumotecan in pretreated locally advanced/metastatic urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-031 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Bladder Cancer
- Interventions
- Sacituzumab tirumotecan; Vinflunine; Docetaxel; Paclitaxel; Rescue medications for sacituzumab tirumotecan; Rescue medications for chemotherapy
- Arms
- Sacituzumab tirumotecan · Experimental
- Chemotherapy · Active comparator
- Enrollment
- 590 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Apr 23, 2026
- Primary completion
- Jul 27, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07419295 · updated Nov 10, 2026